Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy in ED-SCLC
NCT03043599Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 2017
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in small cell lung cancer (SCLC), sponsored by Moffitt Cancer Center. Primary endpoints: Recommended Phase II Dose at 13 weeks and Progression-Free Survival at 6 months. Started Feb 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03043599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043599.